Novo and UCPH-researchers achieve positive results with potential obesity treatment
Researchers from Novo Nordisk and University of Copenhagen achieved promising pre-clinical results with an experimental drug that could potentially beat Novo's popular obesity treatment, Saxenda.
With the launch of Saxenda, Danish Novo Nordisk slowly opened the door to the uncultivated, yet attractive, market for obesity treatment. Just in 2018, Saxenda sold for DKK 4 billion (USD 600 million) globally.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
